Trial Profile
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 01 Feb 2022 Results published in the Aldeyra Therapeutics Media Release.
- 01 Feb 2022 According to an Aldeyra Therapeutics media release, results from the study have been published in the peer-reviewed journal Clinical Ophthalmology.
- 22 Oct 2020 According to an Aldeyra Therapeutics media release, data will be presented in a poster at the American Academy of Ophthalmology 2020 Virtual Annual Meeting (AAO 2020)